CCM
VYNE icon

Cribstone Capital Management’s VYNE Therapeutics VYNE Stock Holding History

Cribstone Capital Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6
Closed – – 466
2021
Q4 		$0 Hold
6
– – ﹤0.01% 417
2021
Q3 		$0 Hold
6
– – ﹤0.01% 410
2021
Q2 		$0 Hold
6
– – ﹤0.01% 355
2021
Q1 		$1K Hold
6
– – ﹤0.01% 322
2020
Q4 		$1K Hold
6
– – ﹤0.01% 312
2020
Q3 		$1K Hold
6
– – ﹤0.01% 284
2020
Q2 		$1K Buy
6
+3
+100% +$406 ﹤0.01% 334
2020
Q1 		$1K Buy
+3
New +$941 ﹤0.01% 333

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
B
Bailard Foster City, California $4.35B AUM 23.57% 1-Year Est. Return

Cribstone Capital Management's VYNE Position: Q1 2022 in Review

Cribstone Capital Management sold out of VYNE Therapeutics (VYNE) in Q1 2022, closing a stake of 6 shares.

Cribstone Capital Management first reported a position in VYNE in Q1 2020 and held it in 8 quarters. The position peaked at $1K in Q1 2021. 44 funds tracked by Wall St. Rank hold VYNE as of Q1 2022.

  • Cribstone Capital Management reported no remaining VYNE Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Cribstone Capital Management sold 6 VYNE Therapeutics shares in Q1 2022.
  • Cribstone Capital Management first reported a position in VYNE Therapeutics in Q1 2020 and held it in 8 quarters.
  • Cribstone Capital Management's VYNE Therapeutics position peaked at $1K in Q1 2021.
  • 44 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2022.

Based on Cribstone Capital Management's 13F filing for Q1 2022, filed 16 May 2022.